N.S. Reed

4.6k total citations · 1 hit paper
26 papers, 2.9k citations indexed

About

N.S. Reed is a scholar working on Reproductive Medicine, Surgery and Oncology. According to data from OpenAlex, N.S. Reed has authored 26 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Reproductive Medicine, 13 papers in Surgery and 8 papers in Oncology. Recurrent topics in N.S. Reed's work include Ovarian cancer diagnosis and treatment (16 papers), Endometrial and Cervical Cancer Treatments (7 papers) and Intraperitoneal and Appendiceal Malignancies (6 papers). N.S. Reed is often cited by papers focused on Ovarian cancer diagnosis and treatment (16 papers), Endometrial and Cervical Cancer Treatments (7 papers) and Intraperitoneal and Appendiceal Malignancies (6 papers). N.S. Reed collaborates with scholars based in United Kingdom, Netherlands and Spain. N.S. Reed's co-authors include Gunnar B. Kristensen, Ignace Vergote, Tom Ehlen, Antonio Casado, Frédéric Amant, Leen Verleye, Nick Johnson, Gavin Stuart, Corneel Coens and René H.M. Verheijen and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

N.S. Reed

25 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer

2010 1.7k citations Ignace Vergote, Claes G. Tropé et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by N.S. Reed

Since Specialization

Citations

This map shows the geographic impact of N.S. Reed's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N.S. Reed with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N.S. Reed more than expected).

Fields of papers citing papers by N.S. Reed

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N.S. Reed. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N.S. Reed. The network helps show where N.S. Reed may publish in the future.

Co-authorship network of co-authors of N.S. Reed

This figure shows the co-authorship network connecting the top 25 collaborators of N.S. Reed. A scholar is included among the top collaborators of N.S. Reed based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N.S. Reed. N.S. Reed is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1150P Search for biomarkers to personalize treatment with streptozotocin plus 5-fluorouracil or everolimus in patients with advanced pancreatic neuroendocrine tumors: The randomized phase III SEQTOR trial (GETNE-1206) 2024 ·Annals of Oncology ·(unknown), Alfonso Scarpa, Rita T. Lawlor, Anguraj Sadanandam, (unknown), Merete Krogh, Àlex Teulé, (unknown), Heinz‐Josef Klümpen, Birgit Cremer, Isabel Sevilla, (unknown), (unknown), J-P. Metges, N.S. Reed, J. Schrader, (unknown), Marino Venerito, (unknown), (unknown)	2
2	1142O Multivariable analysis of streptozotocin plus 5-fluorouracil and everolimus sequences in advanced pancreatic neuroendocrine tumor patients: The SEQTOR trial (GETNE-1206) 2024 ·Annals of Oncology ·(unknown), (unknown), Merete Krogh, Àlex Teulé, (unknown), Heinz‐Josef Klümpen, Birgit Cremer, Isabel Sevilla, (unknown), (unknown), J-P. Metges, N.S. Reed, J. Schrader, Silvia Bozzarelli, (unknown), (unknown), (unknown), Marino Venerito, (unknown), Rafaela Soler	1
3	LBA45 Randomized open label phase III study comparing the efficacy and safety of everolimus followed by chemotherapy (CT) with streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: The SEQTOR study (GETNE 1206) 2022 ·Annals of Oncology ·Ramón Salazar, (unknown), Merete Krogh, Àlex Teulé, (unknown), Heinz‐Josef Klümpen, Birgit Cremer, Isabel Sevilla, Bengt O. Eriksson, (unknown), J-P. Metges, N.S. Reed, J. Schrader, (unknown), Vicente Valentí, Jorge Hernando, (unknown), (unknown), Carlo Carnaghi, Jaume Capdevila	21
4	Neoadjuvant Chemotherapy Versus Debulking Surgery in Advanced Tubo-Ovarian Cancers: Pooled Analysis of Individual Patient Data From the EORTC 55971 and CHORUS Trials 2019 ·Obstetrical & Gynecological Survey ·Ignace Vergote, Corneel Coens, Matthew Nankivell, Gunnar B. Kristensen, Mahesh Parmar, Tom Ehlen, Gordon C. Jayson, Nick Johnson, (unknown), René H.M. Verheijen, W. Glenn McCluggage, Timothy Perren, Pierluigi Benedetti Panici, Gemma G. Kenter, Antonio Casado, César Mendiola, Gavin Stuart, N.S. Reed, Sean Kehoe	30
5	Lymphovascular Space Invasion as a Risk Factor in Early Endometrial Cancer 2016 ·Current Oncology Reports ·Azmat Sadozye, (unknown), N.S. Reed	23
6	Malignant struma ovarii: The west of Scotland experience and review of literature with focus on postoperative management 2012 ·Journal of Medical Imaging and Radiation Oncology ·R.K. Shrimali, (unknown), N.S. Reed	23
7	Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer 2011 ·Annals of Oncology ·Martin Zweifel, Gordon C. Jayson, N.S. Reed, Richard H. Osborne, Bassam Abdul Rasool Hassan, Jonathan A. Ledermann, (unknown), (unknown), (unknown), Jai Balkissoon, David J. Chaplin, Gordon Rustin	135
8	Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer 2011 ·European Journal of Cancer ·Ignace Vergote, Frédéric Amant, Gunnar B. Kristensen, Tom Ehlen, N.S. Reed, Antonio Casado	110
9	Quality of pathology reports for advanced ovarian cancer: Are we missing essential information? 2010 ·European Journal of Cancer ·Leen Verleye, Petronella B. Ottevanger, Gunnar B. Kristensen, Tom Ehlen, Nick Johnson, Maria E.L. van der Burg, N.S. Reed, René H.M. Verheijen, Katja N. Gaarenstroom, Berit Jul Mosgaard, Jose Miguel Seoane, Jacobus van der Velden, Robert Lotocki, Winette van der Graaf, Björn Penninckx, Corneel Coens, Gavin Stuart, Ignace Vergote	27
10	Dose-dense and dose-intense chemotherapy for small cell ovarian cancer: 2 cases and review of literature 2010 ·Medical Oncology ·R.K. Shrimali, (unknown), N.S. Reed	9
11	Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer breakdown → 2010 ·New England Journal of Medicine ·Ignace Vergote, Claes G. Tropé, Frédéric Amant, Gunnar B. Kristensen, Tom Ehlen, Nick Johnson, René H.M. Verheijen, Maria E.L. van der Burg, Ángel J. Lacave, Pierluigi Benedetti Panici, Gemma G. Kenter, Antonio Casado, César Mendiola, Corneel Coens, Leen Verleye, Gavin Stuart, Sërgio Pecorelli, N.S. Reed	1719
12	EORTC–GCG process quality indicators for ovarian cancer surgery 2008 ·European Journal of Cancer ·Leen Verleye, Petronella B. Ottevanger, W. Van der Graaf, N.S. Reed, Ignace Vergote	37
13	Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer 2001 ·British Journal of Cancer ·P. Vasey, R. Atkinson, Robert E. Coleman, Michael Crawford, Margaret Cruickshank, (unknown), Donald R. Fleming, John D. Graham, David E. Parkin, James Paul, N.S. Reed, Stan B. Kaye	64
14	No-carrier-added 123I-MIBG: An initial clinical study in patients with phaeochromocytoma 2000 ·Nuclear Medicine Communications ·(unknown), (unknown), (unknown), (unknown), R. Mairs, J. B. Neilly, N.S. Reed, T. E. Hilditch	20
15	Docetaxel and Cisplatin in Combination as First-Line Chemotherapy for Advanced Epithelial Ovarian Cancer 1999 ·Journal of Clinical Oncology ·P. Vasey, James Paul, (unknown), Elizabeth Junor, N.S. Reed, R.P. Symonds, (unknown), John D. Graham, S. M. Crawford, Robert E. Coleman, H. Thomas, Jo Ann Davis, S. Peter Eggleton, Stan B. Kaye	66
16	Interstitial iridium-192 implantation combined with external radiotherapy in anal cancer: Ten years experience 1998 ·International Journal of Radiation OncologyBiologyPhysics ·Ajay Sandhu, R.P. Symonds, A.G. Robertson, N.S. Reed, (unknown), James Paul	31
17	Chemotherapy for neuroendocrine tumours: The beatson oncology centre experience 1997 ·Clinical Oncology ·M. Hatton, N.S. Reed	17
18	Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group. 1996 ·Journal of Clinical Oncology ·S.B. Kaye, James Paul, J Cassidy, Craig Lewis, Ian D. Duncan, (unknown), Henry C Kitchener, Derek Cruickshank, R. Atkinson, M Soukop, Elaine M. Rankin, Jo Ann Davis, N.S. Reed, S. M. Crawford, Allan MacLean, David E. Parkin, T. K. Sarkar, James H. Kennedy, R.P. Symonds	103
19	Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer 1992 ·The Lancet ·Stan B. Kaye, Craig Lewis, James Paul, M Soukop, Elaine M. Rankin, J Cassidy, Jo Ann Davis, N.S. Reed, Allan MacLean, James H. Kennedy, R.P. Symonds, Ian D. Duncan, (unknown), Henry C Kitchener, Derek Cruickshank, (unknown), T. K. Sarkar, R. Atkinson, S. M. Crawford	126
20	A case of mitozantrone-associated cardiomyopathy without prior anthracycline therapy 1987 ·British Journal of Radiology ·(unknown), N.S. Reed, W.S.J. Ruddell	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact